Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Conor Ernst Steuer, Hidetoshi Hayashi, Wu-Chou Su, Makoto Nishio, Melissa Lynne Johnson, Dong-Wan Kim, Marianna Koczywas, Enriqueta Felip, Kathryn A. Gold, Haruyasu Murakami, Christina S Baik, Sang-We Kim, Egbert F. Smit, Mark Gigantone, Ben Kim, Pang-Dian Fan, Zhenhao Qi, Elaine Y Wu, David W. Sternberg, Pasi A. Janne
Institutions: Winship Cancer Institute, Kindai University, National Cheng Kung University Hospital, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Tennessee Oncology, Seoul National University Hospital, City Of Hope National Medical Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Moores Cancer Center, Shizuoka Cancer Center, Seattle Cancer Care Alliance, University of Washington, Asan Medical Center, University of Ulsan, The Netherlands Cancer Institute, Daiichi Sankyo (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281839860